TY - JOUR
T1 - Biomarkers for EGFR-antagonist response
T2 - In the genes and on the genes!
AU - Easwaran, Hariharan
AU - Baylin, Stephen B.
PY - 2012/4/15
Y1 - 2012/4/15
N2 - Patients with non-small cell lung carcinoma containing epidermal growth factor receptor (EGFR)-activating mutations benefit from EGFR-antagonist therapy. EGFR-antagonist sensitivity is also correlated with epithelial-mesenchymal transition, which Walter and colleagues show to be marked by DNA-methylation changes. If validated, these markers could help identify patients with wild-type EGFR who will benefit from EGFR therapy.
AB - Patients with non-small cell lung carcinoma containing epidermal growth factor receptor (EGFR)-activating mutations benefit from EGFR-antagonist therapy. EGFR-antagonist sensitivity is also correlated with epithelial-mesenchymal transition, which Walter and colleagues show to be marked by DNA-methylation changes. If validated, these markers could help identify patients with wild-type EGFR who will benefit from EGFR therapy.
UR - http://www.scopus.com/inward/record.url?scp=84859880436&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84859880436&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-12-0157
DO - 10.1158/1078-0432.CCR-12-0157
M3 - Short survey
C2 - 22371454
AN - SCOPUS:84859880436
SN - 1078-0432
VL - 18
SP - 2121
EP - 2123
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 8
ER -